Eli Lilly Expands Manufacturing for Zepbound and Mounjaro

The installation of a barrier along I-14 aims to improve safety by discouraging pedestrians from crossing the highway and preventing vehicles from entering oncoming traffic. While this measure addresses several safety concerns, it also poses challenges by making it more difficult, though not impossible, to cross the highway. Additionally, the barrier has been noted to compromise visibility in the area. The I-14 expansion project is expected to be completed within a year.

Eli Lilly is undertaking a significant expansion of its manufacturing site in Lebanon, Indiana, to meet the growing demand for its weight-loss and diabetes treatments, Zepbound and Mounjaro. The company plans to invest $5.3 billion in this expansion, adding $3.7 billion to the $3 billion already allocated for the site. This represents the largest manufacturing investment in Eli Lilly's history, which dates back to the 19th century. The expanded facility will produce tirzepatide, the active ingredient in both Zepbound and Mounjaro, and aims to increase production through 2028. The two drugs generated over $2 billion in sales in the first quarter of this year.